 HOUSTON, May 17, 2021 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. Nasdaq: BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update. 